Rotigotine controlled release - Serina Therapeutics

Drug Profile

Rotigotine controlled release - Serina Therapeutics

Alternative Names: SER-214

Latest Information Update: 29 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Serina Therapeutics
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Parkinson's disease (Early-stage disease) in USA (SC)
  • 26 Oct 2015 SER 214 is available for licensing as of 26 Oct 2015. http://www.serinatherapeutics.com./pipeline/#ser-214
  • 26 Oct 2015 Serina Therapeutics plans a phase-I trial for Parkinson's disease in USA (NCT02579473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top